CG Oncology, Inc. Common stock (CGON) stock analysis

In our weekly check, CG Oncology, Inc. Common stock is graded D (A to F). Of 21 checks on debt, profit, cash flow and trend: 9 pass, warnings: 2, red flags: 10.

About CG Oncology, Inc. Common stock

CG Oncology, Inc. Common stock is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as CGON.

What our checks show for CGON

Red flags

Warning signs

Strengths

Similar companies

BLTE · CAI · ARWR · IBRX · KOD · TXG

Questions

What grade does CG Oncology, Inc. Common stock (CGON) have?

In our weekly check, CG Oncology, Inc. Common stock is graded D (A to F). Of 21 checks on debt, profit, cash flow and trend: 9 pass, warnings: 2, red flags: 10. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of CGON stock?

This week's biggest flags for CG Oncology, Inc. Common stock: Margins falling, Gross margin falling, Weak EPS forecast. In total 12 of 21 checks show a warning or a red flag.

What does CG Oncology, Inc. Common stock do?

CG Oncology, Inc. Common stock is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as CGON.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-11-14

Open the full analysis